Postgraduate Course (I)
Current Issues of Chronic Hepatitis B
Room 201
|
|||||
---|---|---|---|---|---|
13:20-15:00 | |||||
Moderator | Wan-Long Chuang (Kaohsiung) / Han-Chieh Lin (Taipei) |
||||
13:20-13:45 | PG1-1 | Experience from HCV Cure | Chen-Hua Liu | Taipei | |
13:45-14:10 | PG1-2 | Current Strategy for HBV Treatment: Benefit and Challenge | Chien-Hung Chen | Kaohsiung | |
14:10-14:35 | PG1-3 | Hepatitis B Virus Infection and Liver Carcinogenesis | Shiou-Hwei Yeh | Taipei | |
14:35-15:00 | PG1-4 | Clinical and Virological Significance of NTCP Receptor in HBV | Koichi Watashi | Tokyo |
Postgraduate Course (II)
Possible Future Hopes for Treatment of Chronic Hepatitis B
Room 201
|
|||||
---|---|---|---|---|---|
15:20-17:00 | |||||
Moderator | Chiaho Shih (Taipei) / Chia-Yen Dai (Kaohsiung) |
||||
15:20-15:45 | PG2-1 | Overview of HBV Molecular Virology - Unsolved Issues and New Drug (Targets) | Man-Fung Yuen | Hong Kong | |
15:45-16:10 | PG2-2 | Overview of HBV Immunology | Mi-Hua Tao | Taipei | |
16:10-16:35 | PG2-3 | Prospect for the HBV Therapy from the Immunological Approach | Antonio Bertoletti | Singapore | |
16:35-17:00 | PG2-4 | Issues after Hepatitis B Cure --- HBV Reactivation | Yasuhito Tanaka | Nagoya |
Faculty Night
18:30-2100
Faculty Night (by invitation) / 4F VIP Room, TICC
|
---|
Plenary (I): Epidemiology
Impacts of Secondary and Tertiary Prevention in Chronic Hepatitis B Elimination
Room 201 ABC
|
|||||
---|---|---|---|---|---|
08:00-09:40 | |||||
Moderator |
Junko Tanaka
(Hiroshima) /
Sheng-Nan Lu
(Chiayi)
|
||||
08:00-08:25 | PL1-1 | Natural History of Acute and Chronic HBV Infection | Chia-Ming Chu | Taoyuan | |
08:25-08:50 | PL1-2 | Epidemiology and Clinical Significance of Occult HBV Infection | Giovanni Raimondo | Messina | |
08:50-09:15 | PL1-3 | Pathway from the Epidemiological Point of View; Moving towards the Elimination of HBV & HCV in Japan | Junko Tanaka | Hiroshima | |
09:15-09:40 | PL1-4 | Global Epidemiology and Prevention of Chronic Hepatitis B Infection | John Ward | Atlanta |
Plenary (II): Virology
Molecular Virology in New Antiviral Therapies
Room 201 DEF
|
|||||
---|---|---|---|---|---|
08:00-09:40 | |||||
Moderator |
Masashi Mizokami
(Ichikawa)/
Chau-Ting Yeh
(Taoyuan)
|
||||
08:00-08:25 | PL2-1 | Cell Entry Inhibition as an Antiviral Strategy | Koichi Watashi | Tokyo | |
08:25-08:50 | PL2-2 | Complete and Incomplete HBV Particles | Jianming Hu | Hershey | |
08:50-09:15 | PL2-3 | Recent Development of Capsid Modulators/ Inhibitors as New Antiviral Agents | Man-Fung Yuen | Hong Kong | |
09:15-09:40 | PL2-4 | Eliminating cccDNA: Methods and Difficulties | Chau-Ting Yeh | Taoyuan |
Plenary (III): Immunology
Immunological Aspect of Chronic Hepatitis B
Room 201 ABC
|
|||||
---|---|---|---|---|---|
10:00-11:40 | |||||
Moderator |
Antonio Bertoletti
(Singapore) /
Chun-Yen Lin
(Taipei)
|
||||
10:00-10:25 | PL3-1 | The Liver Microenvironment and HBV Immunity | Percy A. Knolle | Munich | |
10:25-10:50 | PL3-2 | Manipulation of the Innate-adaptive Immune Cell Axis in Chronic HBV Infection | Laura Pallett | London | |
10:50-11:15 | PL3-3 | Cure CHB via Targeting Adaptive Immune Response: Animal Experience | Mi-Hua Tao | Taipei | |
11:15-11:40 | PL3-4 | T Cell Therapy for Chronic HBV Infection | Antonio Bertoletti | Singapore |
Plenary (IV): HCV
HCV: Cure and After Cure
Room 201 DEF
|
|||||
---|---|---|---|---|---|
10:00-11:40 | |||||
Moderator |
Geoffrey Dusheiko
(London) /
Jia-Horng Kao
(Taipei)
|
||||
10:00-10:25 | PL4-1 | Epidemiology and Risk Assessment of Hepatitis C Virus Infection in Taiwan | Mei-Hsuan Lee | Taipei | |
10:25-10:50 | PL4-2 | Current Treatment of HCV | Chen-Hua Liu | Taipei | |
10:50-11:15 | PL4-3 | Unmet Needs of Chronic Hepatitis C after SVR | Ming-Lung Yu | Kaohsiung | |
11:15-11:40 | PL4-4 | How to Achieve Global HCV Elimination by 2030? | Geoffrey Dusheiko | London |
Luncheon Symposium
1140-1300
Luncheon Symposium - AbbVie / Room 201 ABC
|
|||
---|---|---|---|
1140-1300
Luncheon Symposium - PharmaEssentia / Room 103
|
Plenary (V): HBV
Challenges and Opportunities in the Diagnosis and Outcomes Prediction of Chronic HBV Infection
Room 201 ABC
|
|||||
---|---|---|---|---|---|
13:00-14:40 | |||||
Moderator |
Yasuhito Tanaka
(Nagoya) /
Chun-Jen Liu
(Taipei)
|
||||
13:00-13:25 | PL5-1 | Advances in the Serologic and Virologic Diagnosis of HBV Infection | Yasuhito Tanaka | Nagoya | |
13:25-13:50 | PL5-2 | Application of Circulating DNA to HBV Induced Liver Pathogenesis | Shiou-Hwei Yeh | Taipei | |
13:50-14:15 | PL5-3 | Application of HCC Risk Scores in Management of CHB Patients | Hwai-I Yang | Taipei | |
14:15-14:40 | PL5-4 | Non-invasive Prediction of HBV Treatment Outcomes Including HCC | Grace Wong | Hong Kong |
Plenary (VI): HDV
Toward Global HDV Control in General and High Risk Populations
Room 201 DEF
|
|||||
---|---|---|---|---|---|
13:00-14:40 | |||||
Moderator |
Camille Sureau
(Paris) /
Jaw-Ching Wu
(Taipei)
|
||||
13:00-13:25 | PL6-1 | HDV Virology and The Novel Therapy for Chronic Hepatitis D | Camille Sureau | Paris | |
13:25-13:50 | PL6-2 | Mechanisms of Large Hepatitis Delta Antigen Induced Epithelial-mesenchymal Transition: Implications of Novel therapy | Jaw-Ching Wu | Taipei | |
13:50-14:15 | PL6-3 | Taiwan-Mongolian Collaboration to Control HDV Infection in a Hyperendemic Area | Davaadorj Duger | Ulaanbaatar | |
14:15-14:40 | PL6-4 | Natural History of Chronic Hepatitis D Virus Infection | Chien-Wei Su | Taipei |
Opening Ceremony
15:00-15:30
Opening Ceremony / Plenary Hall
|
---|
State-of-Art Lecture
Plenary Hall
|
||||
---|---|---|---|---|
15:30-16:00 | ||||
Moderator |
Ding-Shinn Chen
(Taipei)
|
|||
15:30-16:00 | Global Elimination of Hepatitis B: Taiwan Experiences and International Collaborations | Chien-Jen Chen | Taipei |
Chairman Lecture
Plenary Hall
|
||||
---|---|---|---|---|
16:00-16:30 | ||||
Moderator |
Yun-Fan Liaw
(Taoyuan)
|
|||
16:00-16:30 | Towards Hepatitis B Elimination: Taiwan Experience | Rong-Nan Chien | Taoyuan |
Keynote Lecture (I)
Plenary Hall
|
|||||
---|---|---|---|---|---|
16:30-17:00 | |||||
Moderator |
Masao Omata
(Kofu)
|
||||
16:30-17:00 | KL1 | HBeAg-negative Chronic HBV Infection: Natural Course and Management in the Light of HBsAg Quantification | Yun-Fan Liaw | Taoyuan |
Evening Symposium
17:00-18:20
Evening Symposium - Gilead / Plenary Hall
|
---|
Gala Dinner
19:00-21:30
Gala Dinner with Travel Grants / The Grand Hotel
|
---|
Presidential Award - Oral Presentation
Room 201 ABC
|
||||||
---|---|---|---|---|---|---|
07:30-09:00 | ||||||
Moderator |
Geoffrey Dusheiko
(London) / Wan-Long Chuang
(Kaohsiung)
|
|||||
Scientific Judge |
Geoffrey Dusheiko
(London)/ Wan-Long Chuang
(Kaohsiung)/ Takaji Wakita
(Tokyo)/ Cheng-Yuan Peng
(Taichung)/ Chiaho Shih
(Taipei)
|
|||||
07:30-07:38 | O-006 (95) | 4. HBV | Virological and host genetic biomarkers associated with time to clinical relapse following discontinuation of antiviral treatment in chronic hepatitis B patients. | Chau-Ting Yeh | Taoyuan | |
07:39-07:47 | O-007 (106) | 4. HBV | Treatment of non-cirrhotic HBV patients with Inarigivir followed by switch to tenofovir; Final data from cohorts 1 and 2 of the ACHIEVE trial | Chun-jen Liu | Taipei | |
07:48-07:56 | O-008 (141) | 4. HBV | Improved Bone and Renal Safety at 1 Year after Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Results from 2 Phase 3 Studies in Chronic Hepatitis B (CHB) Patients from East Asia | Jia-Horng Kao | Taipei | |
07:57-08:05 | O-010 (182) | 4. HBV | A Novel Fah-/-/Nod-Scid/IL2Rg-/- Based Humanized Mouse Model Generated by CRISPR/Cas-mediated Genome Engineering | Cheng-pu Sun | Taipei | |
08:06-08:14 | O-011 (184) | 4. HBV | Risk of Hepatocellular Cancer and Death/Transplant Between Inactive Hepatitis B and HBeAg-negative Chronic Hepatitis B with Antiviral Agents | Gwang Hyeon Choi | Seoul | |
08:15-08:23 | O-013 (33) | 6. HCV | Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for the treatment of HCV genotype 1b infection without baseline NS5A resistance-associated variants (DARING)-Final report | Ming-lung Yu | Kaohsiung | |
08:24-08:32 | O-015 (198) | 6. HCV | The 1st Year Data of Treatment with DAAs reimbursed by National Health Insurance Taiwan: Mid-term report | Chia-Yen Dai | Kaohsiung | |
08:33-08:41 | O-002 (41) | 3. Immunology | Inhibitory Receptor Co-expression Profiles Of T Cells Co-vary With Tissue Localization In HBV-associated Hepatocellular Carcinoma | Yang Cheng | Singapore | |
08:42-08:50 | O-003 (164) | 3. Immunology | Systemic Administration of Toll-like receptor 9 Agonist Could Alter the Phenotype of Myeloid Derived Suppressor Cells with Subsequent Intrahepatic CD8+ T cell Expansion and Inhibits the Hepatoma Growth | Chien-Hao Huang | Taoyuan | |
08:51-08:59 | O-016 (100) | 8. HCC | Unique substitutions of PreS/S amino acid in HBV-associated HCC patients with the HLA-DPB1*0201 allele | Masaya Sugiyama | Ichikawa |
YIA Presentation
Room 201 DEF
|
||||||
---|---|---|---|---|---|---|
07:30-09:00 | ||||||
Moderator |
Henry Lik-Yuen Chan
(Hong Kong) / Pei-Jer Chen
(Taipei)
|
|||||
Scientific Judge |
Henry Lik-Yuen Chan
(Hong Kong) / Pei-Jer Chen
(Taipei) / Yong Poovorawan
(Bangkok) / Sen-Yung Hsieh
(Taoyuan) / Han-Chieh Lin
(Taipei)
|
|||||
07:30-07:39 | O-001 (67) | 1. Epidemiology | Unchanging High Prevalence of Late Hepatitis B Virus Discovery Among Patients with Chronic Hepatitis B: A Comparison Between Two Time Periods | Stephen Wong | Manila | |
07:40-07:49 | O-004 (74) | 4. HBV | Every-two-week Ropeginterferon Alfa-2B Is Safe with Earlier and Higher Hepatitis B E Antigen Seroconversion in Interferon Naive Patients with Chronic Hepatitis B Virus Infection: A Phase 2, Open-Label, Randomized, Active Control, Dose Finding Study | Yi-Wen Huang | Taipei | |
07:50-07:59 | O-005 (89) | 4. HBV | Serum Mac-2-binding protein glycosylation isomer level at virological remission by antiviral therapy predicts hepatocellular carcinoma and death in chronic hepatitis B patients with cirrhosis | Tung-hung Su | Taipei | |
08:00-08:09 | O-009 (179) | 4. HBV | Cost-Effectiveness of Anti-Viral Treatment in Patients with Immune Tolerant-Phase Chronic Hepatitis B | Hye-lin Kim | Seoul | |
08:10-08:19 | O-012 (192) | 4. HBV | Influence of AFP level during direct antiviral therapy on HBeAg loss | Rachel Wen-juei Jeng | Taipei | |
08:20-08:29 | O-014 (90) | 6. HCV | Outcome of Hepatocellular Carcinoma Patients Undergoing Direct-acting Antivirals Treatment for Chronic Hepatitis C | Chen-Ta Chi | Taipei | |
08:30-08:39 | O-017 (194) | 8. HCC | Hepatitis B core-related antigen is a predictive factor for non-B, non-C hepatocellular carcinoma | Yi-Chung Hsieh | Taoyuan | |
08:40-08:49 | O-018 (34) | 9. Other | Transient elastography is useful in diagnosing biliary atresia and predicting prognosis after hepatoportoenterostomy | Jia-feng Wu | Taipei | |
08:50-08:59 | O-019 (135) | 9. Other | Spleen Stiffness and Splenic Index Predict Esophageal Varices in Patients with Liver Cirrhosis | Wei-Fan Hsu | Taichung |
Keynote Lecture (II)
Plenary Hall
|
|||||
---|---|---|---|---|---|
09:00-09:30 | |||||
Moderator |
Mei-Hwei Chang
(Taipei)
|
||||
09:00-09:30 | KL2 | Toward Global Elimination of Hepatitis B | Anna Suk-Fong Lok | Ann Arbor |
Keynote Lecture (III)
Plenary Hall
|
|||||
---|---|---|---|---|---|
09:30-10:00 | |||||
Moderator |
Pei-Jer Chen
(Taipei)
|
||||
09:30-10:00 | KL3 | Research on HBV Life Cycle and Drug Discovery | Takaji Wakita | Tokyo |
Plenary (VII): HBV
Challenges and Opportunities in the Treatment of CHB
Room 201 ABC
|
|||||
---|---|---|---|---|---|
10:20-12:00 | |||||
Moderator |
Henry Lik-Yuen Chan
(Hong Kong) /
Chun-Jen Liu
(Taipei)
|
||||
10:20-10:45 | PL7-1 | Unmet Needs of CHB after NUC Treatment | Henry Lik Yuen Chan | Hong Kong | |
10:45-11:10 | PL7-2 | Management of CHB Sub-populations with Grey Zone Treatment Indications | Tai-Chung Tseng | Taipei | |
11:10-11:35 | PL7-3 | NUC for CHB: Discontinued Versus Continuous Strategy | Yi-Cheng Chen | Taoyuan | |
11:35-12:00 | PL7-4 | Reactivation of HBV in Special Clinical Settings: Risk and Management | Chun-Jen Liu | Taipei |
Plenary (VIII): HCC
Recent Advance in the Treatment of Hepatocellular Carcinoma
Room 201 DEF
|
|||||
---|---|---|---|---|---|
10:20-12:00 | |||||
Moderator |
Ryosuke Tateishi
(Tokyo)
/
Yi-Hsiang Huang
(Taipei)
|
||||
10:20-10:45 | PL8-1 | Advance in radiofrequency ablation therapy for HCC | Ryosuke Tateishi | Tokyo | |
10:45-11:10 | PL8-2 | Advance in Drug-elution Bead TACE and SIRT for HCC | Yoon-Jun Kim | Seoul | |
11:10-11:35 | PL8-3 | Proton Beam Therapy for HCC | Ji-Hong Hong | Taoyuan | |
11:35-12:00 | PL8-4 | Advance in Immune Checkpoint Inhibitors for HCC | Ann-Lii Cheng | Taipei |
Luncheon Symposium
1200-1320
Luncheon Symposium - BMS / Room 201 ABC
|
|||
---|---|---|---|
1200-1320
Luncheon Symposium - Gilead / Room 201 DEF
|
|||
1200-1320
Luncheon Symposium - MSD / Room 103
|
Special Lecture
Plenary Hall
|
||||
---|---|---|---|---|
13:20-13:40 | ||||
Moderator |
Jia-Horng Kao
(Taipei)
|
|||
13:20-13:40 | Human Genomics and Hepatitis B | Masashi Mizokami | Ichikawa |
Plenary (IX): HBV Vaccination
The Success and Challenge of HBV Vaccination
Room 201 ABC
|
|||||
---|---|---|---|---|---|
13:40-15:20 | |||||
Moderator |
Yong Poovorawan
(Bangkok) /
Yen-Hsuan Ni
(Taipei)
|
||||
13:40-14:05 | PL9-1 | Global Strategies of Hepatitis B Vaccination: The Past, Present and Future | Mei-Hwei Chang | Taipei | |
14:05-14:30 | PL9-2 | The Implementation of HBV Vaccination in South East Asia | Yong Poovorawan | Bangkok | |
14:30-14:55 | PL9-3 | How to Convince People to Implement Universal Vaccination in a Low-endemic Area? | Ayano Inui | Yokohama | |
14:55-15:20 | PL9-4 | Elimination of Mother-to-Child Transmission of HBV | Huey-Ling Chen | Taipei |
Individual Guidelines and Reimbursement Policy on HBV Workshop
Plenary Hall
|
|||||
---|---|---|---|---|---|
13:40-15:20 | |||||
Moderator |
Yun-Fan Liaw
(Taoyuan) /
Anna Suk-Fong Lok
(Ann Arbor) /
Masao Omata
(kofu)
|
||||
13:40-13:50 | IG-1 | The Hong Kong Situation | Vincent Wai-sun Wong | Hong Kong | |
13:50-14:00 | IG-2 | The JSH Guideline for the Antiviral Treatment of Hepatitis B Virus Infection and Current Issues in Japan | Tetsuya Hosaka | Tokyo | |
14:00-14:10 | IG-3 | Korean Guideline and Reimbursement Policy on HBV | Young-Suk Lim | Seoul | |
14:10-14:20 | IG-4 | Current State of Hepatitis B in the Philippines | Stephen N. Wong | Manila | |
14:20-14:30 | IG-5 | Update Reimbursement Guidelines of HBV Therapy in Taiwan and the Long-term Outcomes | Jia-Horng Kao | Taipei | |
14:30-14:40 | IG-6 | Management of Hepatitis B in India: Current Guidelines | Anil Arora | New Delhi | |
14:40-14:50 | IG-7 | A Community Based Hepatitis B Programme in New Zealand to Eliminate Hepatitis B | Susan Hay | Whakatane | |
14:50-15:00 | IG-8 | Simplifying “CHB” Terminology in the Hepatitis B Treatment Guidelines | Rosmawati Mohamed | Kuala Lumpur | |
15:00-15:10 | IG-9 | The Evolving HBV Guidelines and Reimbursement Policies in Mainland China | Jidong Jia | Beijing | |
15:10-15:20 | IG-10 | Armenian Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection | Hasmik Ghazinyan | Yerevan |
Closing Ceremony
15:20-16:00
Closing Ceremony with YIA / Presidential Awards / Plenary Hall
|
---|